Acetarsone, more commonly called stovarsol by the French and Americans and spirocid by the Germans, has been employed in the foreign clinics in the treatment of congenital syphilis since 1924. Numerous reports on the use of this drug have appeared in the foreign literature during the last several years.
It has been only within the last year or two that several American clinicians have begun to use acetarsone (stovarsol) in the treatment of congenital syphilis, and it has been only within the last four or five months that the first three reports have appeared in the American literature. Of these three reports, two have come from clinics in Chicago. In these papers the literature is fully reviewed.
Acetarsone, chemically known as acetylaminohydroxyphenylarsonic acid, is a white tablet which is odorless and is insoluble in water. It is marketed in 0.1 Gm. and 0.25 Gm. tablets. It contains from 27.1 to